Alzheimer’s disease (AD) is a neurodegenerative disease that mainly affects individuals above the age of 65. However, most patients are diagnosed only when significant symptoms appear, by which time severe brain pathology and neuronal cell death have already occurred, resulting in significant brain atrophy. Consequently, the optimal treatment window is often missed, leading to a fatal outcome.
The technology is a simple, non-invasive, and accurate diagnostic solution for Alzheimer’s disease (AD), which can distinguish patients with AD from healthy people and evaluate disease status from a single drop of blood, with more than 96% accuracy. By combining proprietary machine learning algorithms for data analysis, this cutting-edge technology can be applied towards developing a clinical tool for population-scale screening, early diagnosis, staging and monitoring of the disease.
The technology consists of the following main parts:
The global Alzheimer's Disease Diagnostics and Therapeutics Market is expected to reach USD 21.7 billion by 2030, at a CAGR of 5.5% during the forecast period 2021 to 2030. The market for Alzheimer's disease diagnostics and therapies was influenced by the outbreak of the COVID-19 pandemic when it first appeared. The increasing use of biomarkers in Alzheimer's diagnosis and the development of new drugs are the primary factors driving the expansion of the Alzheimer's disease diagnostics and therapeutics market. Another important factor is the rising incidence of Alzheimer's disease worldwide.
The uniqueness of this technology includes several key features:
By combining these features, the technology offers a holistic approach to early detection, risk assessment, and management of AD.